<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03815383</url>
  </required_header>
  <id_info>
    <org_study_id>0203-008</org_study_id>
    <nct_id>NCT03815383</nct_id>
  </id_info>
  <brief_title>A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma</brief_title>
  <official_title>A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, non-randomized and dose-escalation study to evaluate the safety and
      efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include the following sequential phases: Screening, Pre- Treatment (Cell
      Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety:TEAEs</measure>
    <time_frame>30 days</time_frame>
    <description>The incidence of treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>12 months</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>6 months, 12 months</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>C-CAR088</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lymphocytes will be transduced with lentiviral vector containing CAR-BCMA gene</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>C-CAR088</intervention_name>
    <description>Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.</description>
    <arm_group_label>C-CAR088</arm_group_label>
    <other_name>CBM.BCMA Chimeric Antigen Receptor T cell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteered to participate in this study and signed informed consent.

          2. Age 18-75 years old, male or female.

          3. Meet the internationally accepted Criteria for the diagnosis of multiple myeloma (IMWG
             diagnostic criteria 2014).

          4. Patients with relapsed or refractory multiple myeloma.

          5. Subjects have one or more measurable multiple myeloma lesion, must include one of the
             following conditions:

               -  Serum M protein≥1 g/dl(10g/L)

               -  Urine M protein≥200 mg/24h

               -  Serum free light chain(sFLC): κ/λ ratio abnormal and ≥10 mg/dl

          6. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological
             examination.

          7. At least 2 weeks from monoclonal antibody therapy prior to CAR T cell therapy.

          8. ECOG scores 0 - 1.

          9. Normal cardiac diastolic function, left ventricular ejection fraction (LVEF) ≥ 50%
             (detected by echocardiography), no serious arrhythmia.

         10. No active pulmonary infections, normal pulmonary function and oxygen saturation ≥ 92%
             on room air.

         11. No contraindications of leukapheresis.

         12. Expected survival &gt; 12 weeks.

         13. Female subjects in childbearing age, their serum or urine pregnancy test must be
             negative,until 7 days before cell therapy and all subjects must agree to take
             effective contraceptive measures during the trial.

        Exclusion Criteria:

          1. Have a history of allergy to cellular products.

          2. Any kind of these laboratory testing: including but not limited to,serum total
             bilirubin≧1.5mg/dl, serum ALT, AST≧2.5×ULN, serum creatinine≧2.0mg/dl, Hb
             (hemoglobin)&lt;80g/L, neutrophils&lt;1000/mm^3, platelets≦50000/mm^3 or platelet count
             maintained by transfusion.

          3. Subjects with the clinically significant cardiovascular diseases.

          4. A history of craniocerebral trauma, consciousness disorder, epilepsy, severe cerebral
             ischemia or hemorrhagic disease.

          5. Use any anticoagulant (except aspirin).

          6. Patients requiring urgent treatment due to tumor progression or spinal cord
             compression.

          7. Patients with active CNS involvement or clinical syndrome of MM meningeal involvement.

          8. After allogeneic hematopoietic stem cell transplantation.

          9. Plasma cell leukemia.

         10. Subjects with any autoimmune disease or any immune deficiency disease or other disease
             in need of immunosuppressive therapy.

         11. Uncontrolled active infection.

         12. Prior treatment with CAR T therapy or any other genetically modified T cell therapy.

         13. Live vaccine inoculation within four weeks before enrollment.

         14. Hepatitis B or hepatitis C virus infection (including carriers), syphilis, as well as
             acquired, congenital immune deficiency diseases, including but not limited to
             HIV-infected persons.

         15. Have a history of alcoholism, drug addiction and mental illness.

         16. Participated in any other clinical trial within one month.

         17. The investigators believe that there are other circumstances that are not suitable for
             the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianyong Li, PhD</last_name>
    <phone>025-83718836,83714511</phone>
    <email>lijianyonglm@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyong Li, PhD</last_name>
      <email>lijianyonglm@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

